Cygnus nicotine patch
Executive Summary
NDA for the transdermal patch developed for Pharmacia Leo, makers of Nicorette chewing gum, will be filed in "a matter of weeks," President and CEO David de Weese told a Robertson Stephens Medical Conference in New York City Nov. 27. De Weese stressed that the clinical endpoint of Phase III studies of the patch was "total abstenince" verified by checking patient respiration, saliva, and serum. "When looking at clinical data from the competition, I would ask you to keep that in mind," he added. Elan filed an NDA for Nicolan in August 1989, and Marion Merrell Dow expects to file an NDA for Alza's transdermal nicotine in the first quarter of 1990 ("The Pink Sheet" Oct. 29, p. 16).